A transformative cancer therapy based on modified immune cells has lured doctors, companies, and patients alike, but many are hitting a frustrating roadblock: generating enough of these chimeric antigen receptor (CAR)-T cells to meet surging demand. The situation is fluid, with shortages cropping up in some places and easing in others. Doctors, meanwhile, are grappling with how best to distribute the experimental therapy among very sick patients in clinical trials.
{iframe}http://www.sciencemag.org/news/2017/06/experimental-cancer-therapy-struggle-ensure-supply-keeps-demand?utm_source=MIT+Technology+Review&utm_campaign=1f1e1358fb-The_Download&utm_medium=email&utm_term=0_997ed6f472-1f1e1358fb-153904269{/iframe}